Generation Bio
- Company typePrivate
- Founded2020
- HeadquartersCambridge, United States
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Generation Bio firmographics
Firmographics- Name
- Generation Bio
- Legal name
- Generation Bio Co.
- Website
- https://generationbio.com
- Company type
- Private
- Founded year
- 2020
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Ownership category
- akta.pro rank
Generation Bio industry classification
Industry- Product category
- Genetic Medicine
- NAICS
- Pharmaceutical Preparation Manufacturing (325412), Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods) (HLAAACAC)
Keywords
Where Generation Bio is headquartered
LocationHeadquarters
- HQ city
- Cambridge
- HQ country
- United States
- HQ region
- North America
Offices1 record
Markets served
Generation Bio business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Personnel, Technology or R&D, Operations, Others
Revenue model
- Therapeutic Development and Licensing: Pre-revenue clinical-stage company developing gene therapies. Revenue model based on potential future licensing deals and platform monetization through the XOMA acquisition.
Go-to-market motion1 record
Marketing channels1 record
Generation Bio product offering
Product offeringCore offering
Generation Bio developed a non-viral genetic medicines platform built on a proprietary cell-targeted lipid nanoparticle (ctLNP) delivery technology. The platform was designed to deliver siRNA, mRNA, and iqDNA nucleic acid therapies to specific tissues for the treatment of genetic diseases, with a focus on liver diseases, eye conditions, and autoimmune diseases.
Product overview
Generation Bio developed a non-viral genetic medicines platform centered on its cell-targeted lipid nanoparticle (ctLNP) delivery technology. The platform integrates multiple therapeutic modalities including siRNA for gene silencing, mRNA for protein expression, and iqDNA therapies. These technologies are designed to provide durable and redosable treatments for genetic diseases, with a focus on liver diseases, eye conditions, and autoimmune diseases. The ctLNP delivery platform offers advantages over traditional viral vector approaches by enabling targeted tissue delivery and repeat dosing. Generation Bio was acquired by XOMA Royalty Corporation in February 2026.
Differentiator
Problem solved
Functional benefit
Products and services
- Cell-Targeted Lipid Nanoparticle (ctLNP) Delivery Platform A proprietary non-viral delivery platform utilizing cell-targeted lipid nanoparticles to deliver siRNA and nucleic acid therapies to specific tissues and cell types, designed to provide durable and redosable treatments for genetic diseases and offering potential advantages over traditional viral vector approaches.
- siRNA Technology Gene-silencing technology that enables targeted suppression of specific genes, integrated with the ctLNP delivery platform for treating genetic diseases.
- iqDNA Therapies Novel non-viral genetic medicine approach developed for rare and prevalent diseases, extending the company's platform beyond original gene therapy technology.
- mRNA Therapies Non-viral genetic medicines leveraging messenger RNA for therapeutic protein expression, developed using the company's lipid nanoparticle delivery platform.
Companies that use Generation Bio
Customer profileSegments1 record
Ideal customer profiles2 records
Generation Bio technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature2 records
Generation Bio partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- ModernacoreGeneration Bio had a collaboration with Moderna. The acquisition by XOMA included contingent value rights tied to potential proceeds from the Moderna collaboration. CVRs entitle holders to potential payments from Moderna licensing milestones and future platform out-licensing or sales.
Scale indicators5 records
Recent moves5 records
Expansion highlights3 records
Generation Bio competitors and assessment
Company assessmentBroad incumbents
- BioNTech: BioNTech is a global leader in mRNA therapeutics and LNP delivery technology with oncology and infectious disease franchises. Its scale and platform breadth make it a broad incumbent comparable to Generation Bio on core LNP/nucleic acid delivery technology.
- Moderna: Moderna is the global leader in LNP-based mRNA therapeutics and was Generation Bio's strategic partner via the 2023 equity investment and later collaboration. Both companies leverage lipid nanoparticle delivery platforms for nucleic acid-based medicines, making them directly comparable on technology architecture and target indications (liver, rare disease).
Direct peers
- Beam Therapeutics: Beam develops base editing and other precision genetic medicines using both viral and non-viral delivery approaches. As a clinical-stage genetic medicines platform company pursuing liver and other tissue targets, Beam is comparable to Generation Bio in business model and therapeutic positioning.
- Alnylam Pharmaceuticals: Alnylam is the commercial leader in siRNA-based genetic medicines with approved products targeting liver-expressed genes. Generation Bio's ctLNP platform for siRNA delivery in liver indications competes directly with Alnylam's GalNAc-conjugated siRNA platform, making it the closest commercial-stage comparator.
- Intellia Therapeutics: Intellia develops in vivo CRISPR-based gene editing therapies with clinical programs in transthyretin amyloidosis and hereditary angioedema. As a clinical-stage genetic medicines company pursuing durable, single-dose cures, Intellia competes for the same liver-directed genetic disease market that Generation Bio targeted.
- Arcturus Therapeutics: Arcturus develops mRNA-based therapeutics using its STARR® self-amplifying mRNA platform combined with lipid nanoparticle delivery. Comparable to Generation Bio in modality (mRNA + LNP), therapeutic area focus, and clinical-stage development profile.
- Dicerna Pharmaceuticals: Dicerna developed GalNAc-conjugated siRNA therapies for liver-expressed targets before being acquired by Novo Nordisk. Comparable to Generation Bio's siRNA/liver strategy and serves as a relevant precedent for platform biotech M&A outcomes in this space.
- Arrowhead Pharmaceuticals: Arrowhead develops RNAi-based therapeutics using multiple delivery platforms including TRiM™ and lipid nanoparticles for liver and extrahepatic targets. It is a direct competitor to Generation Bio's ctLNP-delivered siRNA programs in hepatic and rare disease indications.
Emerging players
- Verve Therapeutics: Verve is developing in vivo base editing therapies for cardiovascular disease, with liver-directed LNP-delivered programs in early clinical development. Comparable to Generation Bio's ctLNP platform for liver-targeted genetic medicines, though focused specifically on cardiovascular indications.
Others
- Acuitas Therapeutics: Acuitas is a leading LNP technology platform provider whose delivery systems underpin Moderna's COVID-19 vaccine and other mRNA products. As a non-viral delivery infrastructure specialist, Acuitas is thematically comparable to Generation Bio's ctLNP platform on technology rather than competing commercially.
Market position
Strengths4 records
Weaknesses5 records
Competitive moat2 records
Key risks6 records
Key highlights5 records
Customer concentration
Generation Bio social profiles
Digital presenceGeneration Bio financial estimates
Financial estimateRevenue estimate
Valuation estimate
Generation Bio leadership team
Management profileNumber of profiles
Profiles7 records
Generation Bio funding detail
Funding detailFunding overview
Funding rounds5 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Generation Bio M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Generation Bio
What does Generation Bio do?
Generation Bio developed a non-viral genetic medicines platform built on a proprietary cell-targeted lipid nanoparticle (ctLNP) delivery technology. The platform was designed to deliver siRNA, mRNA, and iqDNA nucleic acid therapies to specific tissues for the treatment of genetic diseases, with a focus on liver diseases, eye conditions, and autoimmune diseases.
Is Generation Bio a public or private company?
Generation Bio is a private company. It is classified as corporate owned and is currently acquired.
When was Generation Bio founded?
Generation Bio was founded in 2020. It employs 101 to 250 people.
Where is Generation Bio based?
Generation Bio is headquartered in Cambridge, United States, in the North America region.
How does Generation Bio make money?
One revenue line is on record: therapeutic Development and Licensing.
Who are Generation Bio's main competitors?
Broad incumbents on record are BioNTech and Moderna. Direct peers are Beam Therapeutics, Alnylam Pharmaceuticals, Intellia Therapeutics, Arcturus Therapeutics, Dicerna Pharmaceuticals and Arrowhead Pharmaceuticals. Verve Therapeutics is listed as an emerging player. Acuitas Therapeutics is listed as an others.
Does Generation Bio have an API?
No public API is recorded for Generation Bio.
What industry is Generation Bio in?
Generation Bio's product category is Genetic Medicine. Its primary akta.pro industry code is HLAAACAC, Non-viral Gene Delivery & Gene Therapy (LNP, polymers, electroporation, physical methods). Its NAICS code is 325412 and its SIC code is 2834.